Recombinant A2-specific TNFα-specific antibodies

Details Recombinant A2-specific TNFα-specific antibodies Recombinant A2-specific TNFα-specific antibodies

2007-08-08

2008-05-20

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S141100, C530S387100, C530S387300, C530S388100, C530S388230

Reexamination Certificate

active

07374761

ABSTRACT:
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 5075236 (1991-12-01), Yone et al.
patent: 5223395 (1993-06-01), Gero
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5342613 (1994-08-01), Creaven et al.
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5700788 (1997-12-01), Mongelli et al.
patent: 5730975 (1998-03-01), Hotamisligil et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5776947 (1998-07-01), Kroemer et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5959087 (1999-09-01), Rathjen et al.
patent: 5993833 (1999-11-01), DeLacharriere et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6015558 (2000-01-01), Hotamisligil et al.
patent: 6172202 (2001-01-01), Marcucci et al.
patent: 6190691 (2001-02-01), Mak
patent: 6194451 (2001-02-01), Alpegiani et al.
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6309640 (2001-10-01), Cerami et al.
patent: 6419927 (2002-07-01), Cerami et al.
patent: 6790444 (2004-09-01), Le et al.
patent: 6835823 (2004-12-01), Le et al.
patent: 6991791 (2006-01-01), Le et al.
patent: 7070775 (2006-07-01), Le et al.
patent: 7101674 (2006-09-01), Le et al.
patent: 7128907 (2006-10-01), Le et al.
patent: 7128908 (2006-10-01), Le et al.
patent: 7135178 (2006-11-01), Le et al.
patent: 7135179 (2006-11-01), Le et al.
patent: 7138118 (2006-11-01), Le et al.
patent: 7160542 (2007-01-01), Le et al.
patent: 7160543 (2007-01-01), Le et al.
patent: 7160995 (2007-01-01), Le et al.
patent: 7166284 (2007-01-01), Le et al.
patent: 7169386 (2007-01-01), Le et al.
patent: 7169388 (2007-01-01), Le et al.
patent: 7179466 (2007-02-01), Le et al.
patent: 7179893 (2007-02-01), Le et al.
patent: 7192584 (2007-03-01), Le et al.
patent: 7204985 (2007-04-01), Le et al.
patent: 7214376 (2007-05-01), Le et al.
patent: 7223396 (2007-05-01), Le et al.
patent: 7226593 (2007-06-01), Le et al.
patent: 7227003 (2007-06-01), Le et al.
patent: 7252823 (2007-08-01), Le et al.
patent: 7276239 (2007-10-01), Le et al.
patent: 2002/0146419 (2002-10-01), Le et al.
patent: 2003/0147891 (2003-08-01), Le et al.
patent: 2004/0115200 (2004-06-01), Le et al.
patent: 2005/0249735 (2005-11-01), Le et al.
patent: 2005/0255104 (2005-11-01), Le et al.
patent: 2005/0260201 (2005-11-01), Le et al.
patent: 2006/0024310 (2006-02-01), Le et al.
patent: 2007/0087003 (2007-04-01), Le et al.
patent: 2007/0141057 (2007-06-01), Le et al.
patent: 2007/0196373 (2007-08-01), Le et al.
patent: 0 212 489 (1987-03-01), None
patent: 0 218 868 (1987-04-01), None
patent: 0 260 610 (1988-03-01), None
patent: 0 288 088 (1988-10-01), None
patent: 0 350 690 (1990-01-01), None
patent: 0 351 789 (1990-01-01), None
patent: 0 351 789 (1990-01-01), None
patent: 0387095 (1990-03-01), None
patent: 0 380 068 (1990-08-01), None
patent: 0 393 438 (1990-10-01), None
patent: 0 453 898 (1991-10-01), None
patent: 0 486 526 (1992-05-01), None
patent: 0 512 528 (1992-11-01), None
patent: 0 526 905 (1993-02-01), None
patent: 0 585 705 (1994-03-01), None
patent: 0 614 984 (1994-09-01), None
patent: 0 308 378 (1994-11-01), None
patent: 0 412 486 (1994-11-01), None
patent: 0 101 681 (1994-12-01), None
patent: 0 398 327 (1995-03-01), None
patent: 0 433 900 (1995-09-01), None
patent: 0 663 836 (1997-07-01), None
patent: 02-227095 (1990-09-01), None
patent: WO 61/04750 (1986-03-01), None
patent: WO 89/08460 (1989-09-01), None
patent: WO 90/00902 (1990-02-01), None
patent: WO 90/01950 (1990-03-01), None
patent: WO 02/227095 (1990-09-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 91/04054 (1991-04-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/01059 (1992-01-01), None
patent: WO 92/01472 (1992-02-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 92/13095 (1992-08-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 94/08609 (1994-04-01), None
patent: WO 94/08619 (1994-04-01), None
U.S. Appl. No. 11/401,391, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed Apr. 10, 2006.
U.S. Appl. No. 11/713,534, by Junming Le, Jan T. Vilcek, Peter E. Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel and David J. Shealy, filed Mar. 2, 2007.
U.S. Appl. No. 11/820,214, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed Apr. 18, 2007.
U.S. Appl. No. 11/792,734, by Junming Le, Jan T. Vilcek, Peter E. Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel, and David J. Shealy, filed Dec. 12, 2005.
U.S. Patent Application No. Unknown, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed Dec. 7, 2007.
U.S. Appl. No. 11/713,534, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed Mar. 2, 2007.
U.S. Appl. No. 11/792,734, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed Dec. 13, 2005.
Aderka, D., et al., “IL-6 Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice,”The Journal of Immunology, 143: 3517-3523 (1989).
Aderka, D., et al., “The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases,”Israel J. Med. Sci., 28(2): 126-130 (1992).
Aderka, D., “Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications,”Israel Journal of Medical. Sciences, 27: 52-60 (1991).
Aggarwal, B., et al., “Human Tumor Necrosis Factor Production, Purification and Characterization,”J. of Biol. Chem., 260(4): 2345-2354 (1985).
Akama, H., et al., “Mononuclear Cells Enhance Prostaglandin E2Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α,”Biochemical and Biophysical Research Comm., 168(2): 857-862 (1990).
Alberts, B., et al., Molecular Biology of the Cell, Garland Publishing Inc., pp. 182-183 (1983).
Barbanti, E., et al., “A High-affinity Neutralizing Anti-human TNF-alpha Monoclonal Antibody That Cross-reacts With Human TNF—beta,” Abstracts, Mar. 6-9 (1991).
Barbuto, J.., et al., “Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-infiltrating B Lymphocytes,”Proceedings of the American Association for Cancer Research, 34: 487, Abstract 2904, (1993).
Bendtzen, K., et al., “Auto-Antibodies To IL-Iα and TNFα In Normal Individuals And In Infectious And Immunoinflammatory Disorders,”The Physiological and Pathological Effects of Cytokines, 10B: 447-452 (1990).
Bendtzen, K., et al., “Native Inhibitors (Autoantibodies) of IL-1α and TNF,”Immunology Today, 10(7): 222 (1989).
Beutler, B., et al., “Identity of Tumour Necrosis Factor and the Macrophage-secreted Factor Cachectin,”Nature, 316: 552-554 (1985).
Beutler, B., et al., “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effec

Affiliated with

Also associated with

Rating

Recombinant A2-specific TNFα-specific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant A2-specific TNFα-specific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant A2-specific TNFα-specific antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3981656